Drug Search Results
More Filters [+]

Linagliptin

Alternative Names: linagliptin, tradjenta, bi 1356, trajenta, trazenta, bi-1356, bi1356, jentadueto xr, trijardy xr, glyxambi, jentadueto
Latest Update: 2024-12-13
Latest Update Note: Clinical Trial Update

Product Description

Linagliptin (Trajenta(®), Tradjenta(®)) is a dipeptidyl peptidase (DPP)-4 inhibitor approved for the treatment of adults with type 2 diabetes mellitus in several countries. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/25297911/)

Mechanisms of Action: DPP4 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Pancreatitis | Type 1 Diabetes | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes | Pancreatitis | Type 1 Diabetes | Acidosis | Diabetic Ketoacidosis | General Diabetes | Type 2 Diabetes

Known Adverse Events: Nasopharyngitis | Pharyngitis | Diarrhea | Headache | Enteritis | Gastroenteritis | Respiratory Tract Infections | Constipation | Urinary Tract Infections

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Linagliptin

Countries in Clinic: Argentina, Australia, Brazil, Canada, China, Colombia, Germany, Israel, Korea, Mexico, Puerto Rico, Russia, Thailand, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: Type 2 Diabetes

Phase 1: Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Pancreatic Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DW6013-I-2

P1

Completed

Healthy Volunteers

2023-02-01

28%

DINAMO

P3

Completed

Type 2 Diabetes

2022-10-19

DW6013-I-1

P1

Completed

Healthy Volunteers

2022-10-11

28%

2016-000669-21

P3

Active, not recruiting

Type 2 Diabetes

2022-04-02

Recent News Events